Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tenofovir Monotherapy vs Lamivudine+Adefovir in Suppressed Chronic Hepatitis B
NCT03236584Phase 3Unknown
- Sponsor
- Uijeongbu St. Mary's Hospital
- Start
- Sep 2015
- Primary completion
- Mar 2018
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of tenofovir disoproxil fumarate in Chronic Hepatitis B (CHB) (2 arms), sponsored by Uijeongbu St. Mary's Hospital. Primary endpoint: Sustained Virological Response at 48 weeks. Status: unknown.
02
Drugs
tenofovir disoproxil fumarate
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT03236584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03236584.